COLLECTION · TYPE 2 DIABETES · TIRZEPATIDE
SURPASS Programme
The SURPASS programme — the pivotal randomised trials establishing Tirzepatide's glycaemic and weight effects in adults with type 2 diabetes.
Timeline
- 2021 · LancetSURPASS-1
40-week randomised placebo-controlled Phase 3 monotherapy trial of Tirzepatide 5/10/15 mg in adults with T2D on diet and exercise (Rosenstock et al. 2021).
- 2021 · New England Journal of MedicineSURPASS-2
40-week randomised head-to-head Phase 3 trial of once-weekly Tirzepatide 5/10/15 mg vs once-weekly Semaglutide 1 mg in adults with T2D on metformin (Frías et al. 2021).
- 2021 · LancetSURPASS-3
52-week randomised active-controlled Phase 3 trial of once-weekly Tirzepatide vs once-daily titrated insulin degludec in adults with T2D on metformin ± SGLT2 inhibitor (Ludvik et al. 2021).
- 2021 · LancetSURPASS-4
Randomised active-controlled Phase 3 trial of once-weekly Tirzepatide vs once-daily titrated insulin glargine in adults with T2D and elevated CV risk, with pre-specified CV meta-analysis (Del Prato et al. 2021).
- 2022 · JAMASURPASS-5
40-week randomised placebo-controlled Phase 3 trial of once-weekly Tirzepatide added to titrated insulin glargine in adults with T2D (Dahl et al. 2022).
Compounds
Mechanisms
Research applications
- Glycaemic-control research
- Dual-incretin agonist evidence base
Comparisons
No comparisons attached.
Study count: 5 · Collection updated 2026-11-01.